Sandoz: When Competitors Help Set the Price

Sandoz Inc. agreed to pay $185 million in the Sandoz price fixing settlement announced on October 1, 2021, resolving allegations that arrangements with competing generic manufacturers raised prices paid by federal healthcare programs. A separate state settlement in principle, announced on August 3, 2026, called for $400 million. The agreements addressed different claims against the same generic drug maker.

The Justice Department’s civil settlement announcement placed the alleged arrangements between 2013 and 2015. In the states’ account of the wider industry investigation, competitors met at dinners and golf outings and used phrases such as “fair share” and “playing nice in the sandbox” to describe arrangements that discouraged competition and raised prices. Nice for the sellers. The alleged bargains left taxpayers and patients paying higher prices.

Are Generic Drugs Causing Inflated Prices?

The government alleged that coordination between generic manufacturers inflated prices paid by federal health care programs. In Sandoz’s case, the alleged mechanism was agreement with competitors over price, supply and which customers each would serve. A buyer seeking a better price was dealing with sellers allegedly coordinating the terms of competition.

The alleged deals set the selling price itself, a different practice from drug pricing fraud involving reported benchmarks.

Generic manufacturers sell into a purchasing system that includes wholesalers and buying groups negotiating for pharmacy customers. Wholesalers and large retail customers can buy through shared purchasing ventures. That makes customer allocation commercially important: an agreement about who serves an account can protect the seller’s price at that account. The alleged bargain concerns both the price offered and the rival’s willingness to compete for the business.

Clobetasol and Topical-Drug Price Coordination

Clobetasol, a corticosteroid used to treat skin conditions, was among the Sandoz drugs named in the federal civil settlement. Benazepril HCTZ, used to treat high blood pressure, was another. The drug name connects the broad allegation to a particular product, customer and pricing decision.

The states’ separate topical-drug complaint covered at least 80 generic skin treatments.

For a pricing employee, that product-level view matters. We examine the communication about a particular drug alongside the price decision and customer account it concerned. A discussion about supply, a planned price change and a decision about which accounts to pursue can explain how the alleged arrangement worked inside a commercial team.

How Did Price Fixing Become a False Claims Act Case?

The government alleged that the competitor arrangements were kickbacks that raised federal drug costs, supporting recovery under the False Claims Act. The alleged benefits ran between manufacturers through agreements on price, supply and customer allocation, violating the Anti-Kickback Statute.

In ordinary business terms, the benefit could sit in the agreement governing the sale: the price competitors would support or the customer business they would leave to one another. A competitor leaving an account alone could be valuable to the manufacturer keeping that business.

Pharmacies and physicians submit drug claims, and a manufacturer can cause those claims through its conduct further up the chain. The civil case connects the commercial arrangement to the resulting government expense.

The announcement identified harm to Medicare and Medicaid, and described the investigation’s concern for TRICARE, the military health care program. The Justice Department’s civil fraud teams handled the settlements with investigative support that included the Department of Health and Human Services inspector general.

Pricing Executives Had to Certify Compliance

Sandoz entered a five-year corporate integrity agreement with the Department of Health and Human Services inspector general in connection with the civil settlement. The agreement put pricing transparency and executive accountability into the company’s compliance obligations.

The Justice Department identified internal monitoring, risk assessment programs, provisions to take back executive pay and compliance certifications from executives and board members. It also described a requirement to report price-related information to the inspector general, with individual certifications from key executives involved in pricing and contracting.

Pricing, contracting and compliance staff each see a piece of how a price was approved and certified. We connect those accounts when assessing whether the commercial decisions and the company’s representations tell the same story.

The State Agreement Addressed a Separate Set of Claims

The state agreement covered claims brought by a coalition of 43 states and territories. The California attorney general’s announcement put Sandoz’s total for state-enforcer claims at approximately $469 million, including previous settlements with other states.

The states also alleged that Novartis AG, Sandoz Group AG and Sandoz AG bore responsibility for Sandoz’s conduct and fraudulently transferred assets. That allegation extended their case beyond the U.S. manufacturer’s pricing decisions.

The states’ investigation connected products and prices to the people making commercial decisions. Their account described more than 20 million documents and millions of call-detail records, with contact information for more than 600 sales and pricing personnel across the generics industry.

The states alleged that the social contacts were part of a network of frequent calls, emails and texts. They also described participants using the phrase “responsible competitor” for conduct that discouraged competition. The language made accommodating a rival sound like doing the job properly.

The states said one cooperator’s two-volume notebook recorded discussions with competitors and internal company meetings. Those contemporaneous notes gave investigators an account of the conversations behind the alleged arrangements.

We work with the person who can explain how a competitor conversation related to a later decision about price, supply or a customer.

Other Generic Settlements Followed the Same Payment Connection

Taro Pharmaceuticals and Apotex reached separate civil settlements in the same Justice Department announcement. Taro agreed to pay $213.2 million over allegations involving products including etodolac and nystatin-triamcinolone cream and ointment. Apotex agreed to pay $49 million in connection with pravastatin, used to treat high cholesterol and triglyceride levels.

The drug lists differ, while the government’s civil theory follows the same path: arrangements among manufacturers allegedly raised what federal programs paid.

These pharmaceutical fraud cases put the commercial decision at the center of the payment story. The relevant insider may work where prices are approved or accounts are assigned, well before a pharmacy submits the resulting claim.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Insider information has helped drive pharmaceutical enforcement. Public Citizen’s 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, found that whistleblower revelations were responsible, at least in part, for 54% of federal pharmaceutical settlements during that period.

For a pharmaceutical whistleblower inside pricing or contracting, the contribution may be an explanation of how a particular customer price was chosen and who participated in that decision. We assess that account against the commercial arrangements and the government payments they affected. Product knowledge and an understanding of the business can give meaning to communications that otherwise look routine.

You Know How the Customer Price Was Chosen

If you know how competitor conversations shaped a drug price or customer assignment, talk with our whistleblower experts about what happened inside the business. We develop the case with you and bring in pharmaceutical pricing whistleblower lawyers who understand the connection between competitor arrangements and government payments. We stay beside you to build your strongest pharmaceutical whistleblower case.